ACOG Advises Stopping GLP-1 Drugs Before Pregnancy
The new guidance suggests discontinuing these medications 1 to 2 months before conception to ensure patient safety.
Updated on Oct. 23, 2026 in Diabetes
Live Poll
Do you trust current medical guidance on using weight-loss drugs while breastfeeding or pregnant?
The American College of Obstetricians and Gynecologists issued new clinical guidance advising that GLP-1 receptor agonists be discontinued one to two months before pregnancy. The recommendation stems from limited safety data and the potential risks posed to fetal development by these medications.
Why it matters
Because GLP-1 medications have long half-lives, they can persist in the body well into pregnancy even after a patient stops taking them. This guidance aims to provide clarity for patients and clinicians navigating fertility and metabolic health.
Official guidance based on limited safety data indicates that GLP-1 receptor agonists should be avoided during pregnancy due to concerns over fetal exposure. The long half-life of these drugs complicates management, with discontinuation recommended 1 to 2 months prior to conception.
The players
American College of Obstetricians and Gynecologists
A professional association representing specialists in women's health that establishes clinical standards and practice guidelines.
The details
GLP-1 receptor agonists work by mimicking hormones that regulate appetite and blood sugar, but their extended half-life means the medication remains active in the system for several weeks after the final dose. ACOG advises clinicians to move toward lifestyle interventions during pregnancy instead of pharmacotherapy. For patients breastfeeding, the guidance suggests close monitoring of neonatal weight gain and explicitly advises against GLP-1 use when nursing preterm infants or neonates.
Timeline
October 23, 2026: ACOG released the new clinical guidance.
Health Landscape
This guidance reflects an evolving clinical response to the widespread adoption of weight-loss and diabetes medications. It shifts the standard of care to prioritize reproductive safety until more long-term research on GLP-1 exposure during pregnancy is established.
Patients who are pregnant, breastfeeding, or planning to conceive should review their current medication list with their obstetrician. This is an important topic to discuss with your doctor if you are using GLP-1s obtained through online providers or medical spas.
The takeaway
The lack of safety data on GLP-1 use during pregnancy makes early planning essential for those seeking to conceive. If you are taking these medications, initiate a conversation with your healthcare provider to develop a safe, evidence-based plan for your reproductive journey.
Further reading
For more information on managing metabolic health, visit Diabetes.
Live Poll
Do you trust current medical guidance on using weight-loss drugs while breastfeeding or pregnant?
